Artara Therapeutics Inc (TARA) Stock Price, Quote & News

Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving pare...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 844 0337

Website: www.protaratx.com

Address:

345 Park Avenue South, 3rd Floor, New York, United States

amda Apr. 10 at 6:13 PM

$TARA bounce time...

0 · Reply

amda Apr. 10 at 5:24 PM

$TARA holy moly.....

0 · Reply

amda Apr. 10 at 4:13 PM

$TARA looks like quite a buying opportunity....

1 · Reply

amda Apr. 10 at 3:53 PM

$TARA Highest Price Target 30.00 Average Price Target 25.50 Upside (403.95%) Lowest Price Target 23.00

0 · Reply

amda Apr. 10 at 3:52 PM

$TARA buying the dip $5.07

0 · Reply

Drugtrade Apr. 7 at 6:24 PM

$LXRX $RXRX $TARA long term favorites happy with recent dips buys and adding at these levels

0 · Reply

amda Apr. 6 at 6:07 PM

$TARA loaded new position at $5

0 · Reply

thenumbersdontlie Apr. 1 at 6:33 PM

$TARA gonna be fun when they open the road. Ive got a cycn dumptruck to load up

0 · Reply

Ramanda87 Mar. 31 at 7:52 PM

$TARA this stock has not rebounded since the February 24th results. Market up or down this thing isn’t moving. Analysts still targeting and avg of $26 but idk what to do here, thoughts?…

1 · Reply

RakeTheProfit Mar. 30 at 11:49 PM

$TARA such a good price at these levels.

0 · Reply

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Feb 23, 2026, 5:05 PM EST - 6 weeks ago

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Feb 19, 2026, 8:00 AM EST - 7 weeks ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Feb 2, 2026, 4:05 PM EST - 2 months ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 22, 2026, 8:00 AM EST - 2 months ago

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

Jan 12, 2026, 7:00 AM EST - 3 months ago

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Jan 7, 2026, 8:00 AM EST - 3 months ago

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 3 months ago

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Dec 8, 2025, 4:05 PM EST - 4 months ago

Protara Announces Closing of $75 Million Public Offering

Dec 4, 2025, 10:03 PM EST - 4 months ago

Protara Announces Pricing of $75 Million Public Offering

Dec 4, 2025, 4:15 PM EST - 4 months ago

Protara Announces Proposed Public Offering

Dec 3, 2025, 8:00 AM EST - 4 months ago

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

Dec 1, 2025, 4:15 PM EST - 4 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Nov 19, 2025, 8:00 AM EST - 5 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Nov 18, 2025, 4:30 PM EST - 5 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

Nov 17, 2025, 8:00 AM EST - 5 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

Nov 10, 2025, 8:00 AM EST - 5 months ago

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:05 PM EST - 5 months ago

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

Aug 11, 2025, 8:00 AM EDT - 8 months ago

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 8:00 AM EDT - 10 months ago

Protara Therapeutics Announces Addition to the Russell 3000® Index

Jun 2, 2025, 4:04 PM EDT - 11 months ago

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

May 8, 2025, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 26, 2025, 10:00 AM EDT - 1 year ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Apr 15, 2025, 4:13 PM EDT - 1 year ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Apr 10, 2025, 4:05 PM EDT - 1 year ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Mar 5, 2025, 8:00 AM EST - 1 year ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 26, 2025, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Dec 11, 2024, 4:05 PM EST - 1 year ago

Protara Announces Closing of $100 Million Public Offering

Dec 9, 2024, 11:35 PM EST - 1 year ago

Protara Announces Pricing of $100 Million Public Offering

Dec 5, 2024, 10:50 AM EST - 1 year ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Nov 15, 2024, 5:52 PM EST - 1 year ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 6, 2024, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Sep 9, 2024, 8:05 AM EDT - 1 year ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jun 24, 2024, 5:06 PM EDT - 1 year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2024, 8:00 AM EDT - 2 years ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 2, 2024, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 5, 2024, 8:04 AM EDT - 2 years ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Apr 5, 2024, 8:02 AM EDT - 2 years ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 8:00 AM EST - 2 years ago

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Nov 30, 2023, 8:30 AM EST - 2 years ago

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

amda Apr. 10 at 6:13 PM

$TARA bounce time...

0 · Reply

amda Apr. 10 at 5:24 PM

$TARA holy moly.....

0 · Reply

amda Apr. 10 at 4:13 PM

$TARA looks like quite a buying opportunity....

1 · Reply

amda Apr. 10 at 3:53 PM

$TARA Highest Price Target 30.00 Average Price Target 25.50 Upside (403.95%) Lowest Price Target 23.00

0 · Reply

amda Apr. 10 at 3:52 PM

$TARA buying the dip $5.07

0 · Reply

Drugtrade Apr. 7 at 6:24 PM

$LXRX $RXRX $TARA long term favorites happy with recent dips buys and adding at these levels

0 · Reply

amda Apr. 6 at 6:07 PM

$TARA loaded new position at $5

0 · Reply

thenumbersdontlie Apr. 1 at 6:33 PM

$TARA gonna be fun when they open the road. Ive got a cycn dumptruck to load up

0 · Reply

Ramanda87 Mar. 31 at 7:52 PM

$TARA this stock has not rebounded since the February 24th results. Market up or down this thing isn’t moving. Analysts still targeting and avg of $26 but idk what to do here, thoughts?…

1 · Reply

RakeTheProfit Mar. 30 at 11:49 PM

$TARA such a good price at these levels.

0 · Reply

Abron Mar. 23 at 6:28 PM

$TARA everything is green except this stock.

1 · Reply

thenumbersdontlie Mar. 20 at 10:32 PM

$TARA was the volume at close a rebalance?

1 · Reply

StocktwitsEarnings Mar. 16 at 11:30 AM

$TARA Q4 '25 Earnings Results & Recap Protara Therapeutics expects to incur increasing operating losses for the foreseeable future, requiring additional capital to fund ongoing clinical trials and research. Protara Therapeutics believes its current financial resources are sufficient for at least 12 months.

0 · Reply

Ramanda87 Mar. 12 at 3:56 PM

$TARA this is now trading below the 2/24 pullback a few weeks ago… turn around when?

2 · Reply

beelovjazz Mar. 10 at 1:33 PM

$TARA Its been very quiet on this board for a few days......Proof of life from Tara holders

0 · Reply

AStrokeOfLuck Mar. 4 at 3:22 PM

$TARA

0 · Reply

amda Mar. 4 at 3:01 PM

$TARA loaded new position here at $6.24 avg

0 · Reply

pablo4 Mar. 4 at 2:42 PM

$TARA JP Morgan and others are listening. The Cowen fireside chat yesterday was super-strong as was the Oppenheimer one last week. TARA is super-undervalued, IMO.

1 · Reply

notreload_ai Mar. 4 at 11:55 AM

JPMorgan starts coverage on $TARA with Overweight rating and $27 PT. TARA-002, a de-risked Picibanil replica, targets NMIBC bladder cancer and lymphatic malformations with strong clinical backing from Japan/Taiwan. https://notreload.xyz/jpmorgan-bets-on-protara-therapeutics-overweight-on-picibanil-replica/

0 · Reply

SuperGreenToday Mar. 2 at 8:12 PM

$TARA Share Price: $6.01 Contract Selected: Aug 21, 2026 $5 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.31 – $0.38 Potential Upside: 72% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

pablo4 Feb. 27 at 11:59 PM

$TARA listen to the last 1 minute of the Oppenheimer webcast available now at TARA's website. You'll want to hold your TARA shares, IMO.

0 · Reply

pablo4 Feb. 27 at 11:56 PM

$TARA just listened to fireside chat with Oppenheimer from yesterday....very informative. TARA's CEO is excellent, IMO. He's a great messenger too for the company. LM is fixing to take front and center. If the PR voucher program is re-approved by Congress, the last voucher sold for 205M. TARA will have a voucher if it gets to LM approval which looks pretty certain to me. JMO

1 · Reply

Market Cap	277.99M
Revenue (ttm)	0.00
Net Income (ttm)	-57.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	547,857
Avg Vol	1,020,790
Day's Range	N/A - N/A
Shares Out	54.08M
Stochastic %K	75%
Beta	1.50
Analysts	Strong Sell
Price Target	$25.71